<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1)" exact="infection" post="and the development of novel therapeutic approaches against HIV-1,"/>
 <result pre="perspective strategy is focused on finding proteins involved in the" exact="infection" post="process caused by both studied and well-known agents using"/>
 <result pre="usage of known antiviral drugs, including those employed for the" exact="treatment" post="of viral hepatitis C and antiretroviral drugs, to treat"/>
 <result pre="to treat SARS-CoV-2 [7,8,9]. There are several studies describing the" exact="treatment" post="of SARS-CoV-2 using antiretroviral drugs, such as remdesivir [10],"/>
 <result pre="of lopinavir/ritonavir has been discussed [12,13,14]. Their application for the" exact="treatment" post="of COVID-19 as monotherapies [12] or in combination with"/>
 <result pre="could shed light on novel potential therapeutic approaches for the" exact="treatment" post="of COVID-19. SARS-CoV-2 and HIV-1 belong to different virus"/>
 <result pre="gastrointestinal tract [23]. There are therapeutic strategies to combat HIV-1" exact="infection" post="in addition to combination antiretroviral therapy, which is currently"/>
 <result pre="used to treat HIV-infection [24]. Other approaches to combat HIV-1" exact="infection" post="include novel strategies such as disrupting the CCR5 gene"/>
 <result pre="low-molecular-weight drugs targeting SARS-CoV-2 is ongoing, but some currently applied" exact="treatment" post="strategies include the use of some known drugs such"/>
 <result pre="ritonavir) [30]. The therapeutic effects of medicines applied for the" exact="treatment" post="of rheumatoid arthritis [31] along with those of some"/>
 <result pre="SARS-CoV-2 have generated interest in identifying similar mechanisms of viral" exact="infection" post="shared by SARS-CoV-2 and HIV-1, in particular their effects"/>
 <result pre="the main processes associated with targets currently validated for the" exact="treatment" post="of different pathological conditions and diseases. We discuss our"/>
 <result pre="as a promising one to combat viral infections including HIV-1" exact="infection" post="and COVID-19 [45]. The proteins cathepsin B and L,"/>
 <result pre="used by HIV-1 variants that do not require CD4 for" exact="infection" post="[49]. There is evidence that an interaction of SARS-CoV-2"/>
 <result pre="We analyzed the sets of currently validated targets for the" exact="treatment" post="of certain diseases and pathological conditions. According to these"/>
 <result pre="proteins, their role in inflammation and the immune response during" exact="infection" post="is well studied [76]. The second group contains a"/>
 <result pre="to better understand the effectiveness of approved drugs for the" exact="treatment" post="of SARS-Co-V2 when specific antiviral medicines are not known."/>
 <result pre="full list of proteins related to the development of SARS-CoV-1" exact="infection" post="only in Table S3 of the Supplementary Materials. Summarizing"/>
 <result pre="which should be taken into account for the development of" exact="treatment" post="strategies based on existing drugs. We believe that the"/>
 <result pre="found as belonging to the set of validated targets for" exact="treatment" post="pathological conditions and diseases according to the Integrity database,"/>
 <result pre="List of human proteins involved in the development of the" exact="infection" post="caused by SARS-CoV-1 according to the text and data"/>
 <result pre="drug repositioning as a short-term strategy for the control and" exact="treatment" post="of COVID-19 (SARS-CoV-2): A systematic reviewArch. Virol.202010.1007/s00705-020-04693-532514689 15.WangX.XuW.HuG.XiaS.SunZ.LiuZ.XieY.ZhangR.JiangS.LuL.SARS-CoV-2 infects"/>
 <result pre="storm is ragingJ. Clin. Invest.2020130220210.1172/JCI13764732217834 34.ClayC.C.DonartN.FomukongN.KnightJ.B.OverheimK.TipperJ.Van WestrienenJ.HahnF.HarrodK.S.Severe acute respiratory syndrome-coronavirus" exact="infection" post="in aged nonhuman primates is associated with modulated pulmonary"/>
 <result pre="Pathophysiological InsightsJ. Stroke Cerebrovasc. Dis.20202910494110.1016/j.jstrokecerebrovasdis.2020.104941 49.YoshiiH.KamiyamaH.GotoK.OishiK.KatunumaN.TanakaY.HayashiH.MatsuyamaT.SatoH.YamamotoN.et al.CD4-independent human immunodeficiency virus" exact="infection" post="involves participation of endocytosis and cathepsin BPLoS ONE20116e1935210.1371/journal.pone.001935221541353 50.OuX.LiuY.LeiX.LiP.MiD.RenL.GuoL.GuoR.ChenT.HuJ.et"/>
 <result pre="cross-reactivity with SARS-CoVNat. Commun.202011162010.1038/s41467-020-15562-932221306 51.LiuT.LuoS.LibbyP.ShiG.P.Cathepsin L-selective inhibitors: A potentially promising" exact="treatment" post="for COVID-19 patientsPharmacol. Ther.202021310758710.1016/j.pharmthera.2020.107587 52.HopkinsJ.YadavalliT.AgelidisA.M.ShuklaD.Host Enzymes Heparanase and Cathepsin"/>
 <result pre="B and cystatin B in HIV-seropositive women are associated with" exact="infection" post="and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe Acute Respiratory Syndrome"/>
</results>
